Nicholas Jacobus

A federal court’s decision to temporarily allow continued mail distribution of mifepristone underscores the ongoing legal and regulatory uncertainty surrounding abortion access.

Shah Capital escalates its pressure campaign against Novavax leadership, requesting changes and strategic overhauls amid ongoing performance concerns.

Disruptions from the U.S.and Iran conflict moves across key transit routes and threatens the flow of active ingredients, price spikes, and heightened risk of drug shortages worldwide.

In today's Pharmaceutical Executive Daily, Novo Nordisk launches Wegovy HD nationwide across the U.S., Gilead Sciences agrees to acquire German antibody-drug conjugate biotech Tubulis for up to $5 billion, and Pharmaceutical Executive marks World Health Day 2026 with a collection of voices from industry leaders on what it means to stand with science.

Novo Nordisk’s U.S. launch of a higher-dose Wegovy formulation highlights Novo's effort to extend efficacy, capture broader patient demand, and reinforce its dominance in the rapidly expanding obesity market.

Gilead Sciences’ acquisition of Tubulis underscores the intensifying industry focus on antibody-drug conjugates as a key frontier in oncology treatment.

Industry leaders highlight how evidence-based decision-making remains central as World Health Day 2026 emphasizes the theme of standing with science.

In today's Pharmaceutical Executive Daily, Neurocrine Biosciences agrees to acquire Soleno Therapeutics for $2.9 billion to gain Vykat XR, the first approved treatment for hyperphagia in Prader-Willi syndrome, BioNTech announces it will close its Singapore vaccine manufacturing facility by February 2027 as declining Covid revenues drive a strategic pivot, and Pharmaceutical Executive examines two emerging frameworks that specialty drug manufacturers are using to protect patient access and benefit savings in a shifting payer environment.

BioNTech’s decision to close its Singapore manufacturing facility reflects mounting financial pressure, ongoing restructuring efforts, and uncertainty around the pace at which next-generation mRNA therapies will scale.

Neurocrine Biosciences’ planned $2.9 billion acquisition of Soleno Therapeutics includes the addition of Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome.

In today's Pharmaceutical Executive Daily, President Trump signs an executive order imposing 100% tariffs on imported patented pharmaceuticals under Section 232, with significant carve-outs for companies that have struck MFN pricing deals or committed to domestic manufacturing, Pfizer and BioNTech halt a large post-marketing Covid-19 vaccine trial in healthy adults aged 50 to 64 after failing to hit enrollment targets, and a new analysis examines how the industry is adapting strategically to a fundamentally transformed U.S. pricing environment.

Pfizer and BioNTech halted a large U.S. clinical trial targeting healthy adults aged 50 to 64 after enrollment shortfalls made it impossible to generate the post-marketing data the FDA required.

In today’s Pharmaceutical Executive Daily, leadership turnover continues across key federal health agencies under the Trump administration, Shionogi enters a $2 billion agreement to acquire rights to Radicava, and the FTC examines antitrust concerns tied to CVS Health’s integrated healthcare model.

Shionogi completed its $2.5 billion acquisition of global rights to Radicava from Tanabe Pharma, adding one of the few approved treatments for ALS to its portfolio .

Since the start of President Trump's second term, the FDA, CDC, CDER, and CBER have collectively cycled through more than a dozen leadership changes.

FDA has approved Foundayo, Eli Lilly's once-daily oral GLP-1 receptor agonist, as the first small molecule pill of its kind for obesity.

In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK Jr.'s vaccine policy overhaul as political pressures mount ahead of the midterm elections, Biogen agrees to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, and Pharmaceutical Executive examines the risk-reward calculus facing R&D leaders in today's volatile development environment.

A federal court setback on childhood vaccine policy has left the White House weighing legal options against electoral risks, as it navigates pressure from its MAHA base alongside broader public support for immunization programs.

Biogen acquires Apellis Pharmaceuticals in a deal that brings two marketed complement therapies into its portfolio, strengthening its position in immunology.

In today's Pharmaceutical Executive Daily, Novo Nordisk launches the first multi-month subscription program for Wegovy targeting cash-paying patients through telehealth partners, Merck enters an $838 million research collaboration with antibody discovery startup Infinimmune, and Eli Lilly agrees to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion to expand into sleep-wake disorder treatments.

Novo Nordisk launched a multi-month Wegovy subscription program offering fixed monthly pricing through telehealth providers, aiming to improve affordability and long-term adherence among self-pay patients.

Merck is partnering with Infinimmune in a deal worth up to $838 million to leverage AI-driven antibody discovery.

Eli Lilly agreed to acquire Centessa Pharmaceuticals for approximately $7.8 billion, expanding its neuroscience pipeline.

In today's Pharmaceutical Executive Daily, Eli Lilly presses the U.K. government to overhaul its NHS drug pricing framework as a condition of resuming investment in the country, Lilly also announces a deal worth up to $2.75 billion with AI drug discovery company Insilico Medicine to accelerate development of novel therapeutics across multiple disease areas, and Pharmaceutical Executive speaks with the co-founder and CEO of Soley Therapeutics about the company's biology-first approach to drug discovery.

Eli Lilly warns that the UK's current framework is undermining investment and could impact future launches and manufacturing decisions.

The agreement grants Lilly an exclusive worldwide license to a portfolio of preclinical oral therapeutics.

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire Excellergy for up to $2 billion to advance a next-generation anti-IgE therapy while Otsuka moves to acquire Transcend Therapeutics in a deal valued at up to $1.225 billion, the FDA approves two first-of-their-kind therapies in Novo Nordisk's once-weekly basal insulin Awiqli and Rocket Pharmaceuticals' gene therapy Kresladi for a rare pediatric immune disease, and a new commentary argues that orphan drug manufacturers should be proactively evaluating risk contracting as a hedge against an emerging downward pricing environment.

Kresladi becomes the first FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2, and Awiqli the first and only once-weekly basal insulin treatment for adults with type 2 diabetes.

Novartis and Otsuka Pharmaceutical are advancing deals to expand pipelines in allergy and psychiatry, with Novartis targeting next-generation anti-IgE therapy and Otsuka betting on a rapid-acting PTSD treatment.

In today's Pharmaceutical Executive Daily, the Trump administration misses a statutory deadline to nominate a permanent CDC director, leaving the agency in continued leadership limbo, the FDA grants accelerated approval to Denali Therapeutics' Avlayah as the first therapy designed to cross the blood-brain barrier and treat the neurological manifestations of Hunter syndrome, and a new commentary breaks down what CMS's updated ASP reporting requirements mean for Part B drug manufacturers ahead of a key April deadline.